Current Osteoporosis Reports

, Volume 16, Issue 6, pp 772–774 | Cite as

Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?

  • Stuart SilvermanEmail author
  • Deborah T. Gold
Invited Commentary


Patients at high risk of fracture often do not take medication for osteoporosis. Recent literature may give us some insights into why patients at high risk of fracture do not take medications for osteoporosis.


Medication decision-making Adherence Osteoporosis 


Compliance with Ethical Standards

Conflict of Interest

Stuart Silverman and Deborah Gold declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Guggina P, Flahive J, Hooven FH, et al. Characteristics associated with anti-osteoporosis medication use data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone. 2012;51:975–80.CrossRefGoogle Scholar
  2. 2.
    Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, et al. Primary nonadherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int. 2013;24:2509–17.CrossRefGoogle Scholar
  3. 3.
    Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteop Rep. 2006;4:21–7.CrossRefGoogle Scholar
  4. 4.
    Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord. 2010;11:275–80.CrossRefGoogle Scholar
  5. 5.
    Fischoff B, Slovic P, Lichtenstein S, et al. How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits. Policy Sci. 1978;9:127–52.CrossRefGoogle Scholar
  6. 6.
    Weiss TW, Gold DT, Silverman SL, McHorney CA. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin. 2006;22:949–60.CrossRefGoogle Scholar
  7. 7.
    Silverman S, Calderon A, Kaw K, Childers TB, Stafford BA, Brynildsen W, et al. Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis. Osteoporos Int. 2013;24:2067–77.CrossRefGoogle Scholar
  8. 8.
    Lloyd AJ. The extent of patients’ understanding of the risk of treatments. Quality Health Care. 2001;10(suppl 1):i4–i18.Google Scholar
  9. 9.
    Weinstein ND. Optimistic biases about personal risks. Science. 1989;246:1232–3.CrossRefGoogle Scholar
  10. 10.
    Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE, et al. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int. 2011;22:27–35.CrossRefGoogle Scholar
  11. 11.
    Redelmeier DA, Rozin P, Kahneman D. Understanding patients’ decisions: cognitive and emotional perspectives. JAMA. 1993;27:72–6.CrossRefGoogle Scholar
  12. 12.
    Paling J. Strategies to help patients understand risk. BMJ. 2003;327:745–8.CrossRefGoogle Scholar
  13. 13.
    Bennett. Understanding response to risk: some basic findings. In: Bennett P, Calman K, editors. Risk communication and public health. Oxford: Oxford Medical Publications; 1999. p. 3–19.Google Scholar
  14. 14.
    Silverman S, Qu H, Curtis J, et. al. Understanding physicians’ perceptions of patients’ barriers to osteoporosis medication initiation. Presented at ASBMR; 2014. Available at Accessed 28 Feb 2015.
  15. 15.
    Kessels RC. Patients’ memory for medical information. J R Soc Med. 2003;96(5):219–22.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Anderson JL, Dodman S, Kopelman M, Fleming A. Patient information recall in a rheumatology clinic. Rheumatol Rehabil. 1979;18:245–55.CrossRefGoogle Scholar
  17. 17.
    Campos B, Schetter CD, Abdou CM, Hobel CJ, Glynn LM, Sandman CA. Familialism, social support and stress: positive implications for pregnant Latinas. Cult Divers Ethn Minor Psychol. 2008;14:155–62.CrossRefGoogle Scholar
  18. 18.
    Silverman SL, Greenwald M, Klein RA, et al. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89:321–5.CrossRefGoogle Scholar
  19. 19.
    Wang C, O’Neill RN, et al. Comparison of risk perceptions and beliefs across common chronic diseases. Prev Med. 2009;48:197–202.CrossRefGoogle Scholar
  20. 20.
    Solimeo SL, Weber TJ, Gold DT. Older men’s explanatory model for osteoporosis. The Gerontologist. 2011;51(4):530–9.CrossRefGoogle Scholar
  21. 21.
    Hutchins R, Viera AJ, Sheridan SL, Pignone MP. Quantifying the utility of taking pills for cardiovascular prevention. Circ Cardiovasc Qual Outcomes. 2015;8:155–63.CrossRefGoogle Scholar
  22. 22.
    Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47(3):334–41.CrossRefGoogle Scholar
  23. 23.
    Reyna VF, al NWLE. How numeracy influences risk comprehension and medical decision making. Psychol Bull. 2009;135:943–73.CrossRefGoogle Scholar
  24. 24.
    Grimes DA, Snively GR. Patients understanding of medical risks: implications for genetic counseling. Obstet Gynecol. 1999;93:910–4.PubMedGoogle Scholar
  25. 25.
    Leblanc A, Wang AT, Wyatt K, et al. Encounter decision aid vs. clinical decision support or usual care to support patient-centered treatment decisions in osteoporosis: the osteoporosis choice randomized trial II. PLoS One. 2015;10(5):e0128063. eCollection 2015.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cedars-Sinai Medical Center and David Geffen School of MedicineLos AngelesUSA
  2. 2.OMC Clinical Research CenterBeverly HillsUSA
  3. 3.Duke University Medical CenterDurhamUSA

Personalised recommendations